Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients
about
Advances and hurdles on the way toward a leprosy vaccine.The continuing challenges of leprosyThalidomide inhibits the replication of human immunodeficiency virus type 1Mycobacterium leprae actively modulates the cytokine response in naive human monocytes.Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathyCytokine production at the site of disease in human tuberculosisSix-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis.Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components.Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.Interleukin 12 at the site of disease in tuberculosis.Thalidomide: a remarkable comeback.Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease.Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals.Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression.Thalidomide Prevents Alcoholic Liver Injury in Rats Through Inhibition of Kupffer Cell SensitizationAnti-inflammatory strategies in alcoholic steatohepatitis.Thalidomide: mechanisms of action.Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.Leprosy as a model of immunity.Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.Genetic polymorphisms of the IL6 and NOD2 genes are risk factors for inflammatory reactions in leprosyIntegrated pathways for neutrophil recruitment and inflammation in leprosy.Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.Thalidomide revisited: pharmacology and clinical applications.Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha.Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.Expression and cytokine secretion in the states of immune reactivation in leprosy.The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions.The study of Mycobacterium leprae infection in interferon-gamma gene--disrupted mice as a model to explore the immunopathologic spectrum of leprosy.Emerging Concepts of Adaptive Immunity in Leprosy.Serum Th1/Th2 and macrophage lineage cytokines in leprosy; correlation with circulating CD4(+) CD25(high) FoxP3(+) T-regs cells.The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression.Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation
P2860
Q22305432-760B95C9-0B8B-4671-B4C9-2DC6A70351FFQ24545809-B49CE278-20D3-43E3-9255-A688B589891BQ28378516-BC16CBF1-1EC2-4D7B-B303-5C186B02B5A9Q33557846-55AD9421-6CE4-45A0-85CC-249034B9681DQ33566870-41712639-4A3B-4C54-9765-20168B121E56Q33605785-1B6879AA-27CC-47DC-8383-6B0D3FCC25FBQ33654669-D660EB0A-2A3D-41C1-92C8-77157FDBB710Q33899146-653DA12D-99F8-4318-ADCC-C64A56890DF4Q33973488-2D5E91E8-5529-4DC4-A4D8-BDBD008C8DAAQ34140928-3FE96092-CB45-4D62-9381-6AE70267D431Q34182143-FDA73B17-D263-479B-92EC-6CACE7D8DECCQ35198923-D5ED47D6-7E63-4406-98D7-9C6645E03583Q35372676-1ABEF7D1-1DAE-44AF-89F8-867F59A0727DQ35410293-6D8CA342-C244-49F1-B2D9-5484E2DC14A4Q35474954-86C4DE52-BAD4-413C-9457-65DE252648F0Q36697035-E460F465-F4ED-4F59-B340-33065FC0CA97Q36849052-8EE16035-DC7E-4F7A-8BFA-D4A1AE422E46Q37147933-F9CBDD97-08DF-4D3C-9209-9CB1C5E56E9BQ37451046-4EE63576-2CE3-455D-995D-CB925FBE3F3AQ37695062-ABE44C0F-B1F5-4F5F-A3B7-C5B72AE01F13Q39297097-C8713ADD-1AF0-4988-945A-9D06C4C541DAQ40163734-2EA9015D-C3C1-4E3E-8514-758BA3170B00Q41154742-3E7DC7E8-5F12-43F7-A402-EFEB3B2B1903Q42930976-ED03AEC8-4213-49E9-B017-526155560B09Q42941758-F08488A2-5F43-495D-A73F-8C48287EE217Q43596294-B70D0982-C75E-4A36-953F-A441298F3606Q44412691-1E3C2AE5-273B-4EB7-BD18-2536FCE282CBQ46648179-B7A75118-A19E-4090-9343-806EC8F4AD6FQ47758480-E429BC03-F1C6-481C-88C5-7EC8838359B4Q50285516-47F520BB-4CB2-43FC-801C-4426A0BEF2C7Q52545418-C7710E83-72D6-4B2D-8D4C-8D3542E86EC6Q52568336-9D847D39-7A9E-4E52-8158-5C9FE095286DQ53833059-9EF5D8DA-EFDA-4B18-BA97-95EE77BA1ACDQ54372448-47661EF7-2661-4C16-8E31-C222BCE4A422Q57450697-BBB97A1F-E870-4062-95B2-B886534913A8
P2860
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Prolonged treatment with recom ...... n lepromatous leprosy patients
@ast
Prolonged treatment with recom ...... n lepromatous leprosy patients
@en
type
label
Prolonged treatment with recom ...... n lepromatous leprosy patients
@ast
Prolonged treatment with recom ...... n lepromatous leprosy patients
@en
prefLabel
Prolonged treatment with recom ...... n lepromatous leprosy patients
@ast
Prolonged treatment with recom ...... n lepromatous leprosy patients
@en
P2093
P2860
P356
P1476
Prolonged treatment with recom ...... n lepromatous leprosy patients
@en
P2093
P2860
P304
P356
10.1084/JEM.175.6.1729
P407
P577
1992-06-01T00:00:00Z